| Literature DB >> 32938461 |
Miranda W Langendam1, Thomas Piggott2, Monika Nothacker3, Arnav Agarwal4, David Armstrong5, Tejan Baldeh1, Jeffrey Braithwaite6, Carolina Castro Martins2,7, Andrea Darzi2, Itziar Etxeandia8, Ivan Florez1,9, Jan Hoving10, Samer G Karam2, Thomas Kötter11, Joerg J Meerpohl12, Reem A Mustafa2,13, Giovanna E U Muti-Schünemann14, Philip J van der Wees15, Markus Follmann16, Holger J Schünemann17,18,19.
Abstract
BACKGROUND: Guidelines and quality indicators (for example as part of a quality assurance scheme) aim to improve health care delivery and health outcomes. Ideally, the development of quality indicators should be grounded in evidence-based, trustworthy guideline recommendations. However, anecdotally, guidelines and quality assurance schemes are developed independently, by different groups of experts who employ different methodologies. We conducted an extension and update of a previous systematic review to identify, describe and evaluate approaches to the integrated development of guidelines and related quality indicators.Entities:
Keywords: Guidelines; Quality assurance; Quality improvement; Recommendations
Year: 2020 PMID: 32938461 PMCID: PMC7493171 DOI: 10.1186/s12913-020-05665-w
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1a Flow chart original review by Kötter et al. b Flow chart update original systematic review by Kötter et al.
General characteristics of the included method papers
| Reference | Institution (country) | Topic | Setting | Funding |
|---|---|---|---|---|
| Advani 2003 [ | BMIR (US) | Hypertension | – | Public |
AHCPR 1995 [ AHRQ 1995 [ Hughes 2008 [ | AHRQ (US) | – | – | Combined public/private |
AQUA 2010 [ AQUA 2013 [ | AQUA (DE) | – | – | Not reported |
ÄZQ 2011 [ Nothacker 2011 [ | ÄZQ (DE) | Chronic heart failure | – | Public/private |
| Baker 1995 [ | Eli Lilly National Clinical Audit Centre (UK) | – | – | Not reported |
| Bayley 2018 [ | Institute National d‘Excellence en sante et en services sociaux (INESS/ONF) (CA) | Traumatic brain injury | – | Public |
| Califf 2002 [ | DCRI (US) | Cardiovascular medicine | All | Public |
| Cottrell 2018 [ | American Rhinological Society (US) | Chronic rhinosinusitus | All | Not reported |
| Cheng 2010 [ | American Academy of Neurology (US) | Parkinson disease | All | Not reported |
| Davies 2011 [ | University Bristol (UK) | Wound, end of life and diabetes care | Outpatient care | Public |
| Duffy 2005 [ | APIRE (US) | Bipolar disorder | Outpatient care | Not reported |
| Fiset 2019 [ | University of Ottawa School of Nursing (CA) | Pain management | Inpatient, outpatient, long-term care, palliative | Not reported |
| Follmann 2017 [ | German Guideline Program in Oncology (GGPO) (DE) | Oncology | Not reported | |
| Golden 2008 [ | UAMS (US) | Bipolar disorder | Rehabilitation | Public |
| Graham 2009 [ | Immpact (UK) | – | All | Public |
| Hommel 2016 [ | Internal Medicine and IQ healthcare, Radboud UMC (NL) | Perioperative diabetes care | All | Public |
| Hutchinson 2003 [ | ScHARR (UK) | CHD | Hospital | Combinedpublic/private |
| Kahn 2014 [ | American Thoracic Society (ATS) (US) | Pulmonary, critical care, and sleep medicine | – | Not reported |
| Laclair 2001 [ | VA Medical Center (US) | Stroke | Rehabilitation | Public |
| Luitjes 2013 [ | Dutch Society for Obstetrics and Gynaecology and IQ healthcare, Radboud UMC (NL) | Hypertensive diseases in pregnancy | Hospital | Public |
| Mazzone 2014 [ | American College of Chest Physicians (CHEST)(US) | Lung cancer | District nursing | Private non-profit |
| Rushforth 2015 [ | University Leeds (UK) | – | Hospital | Public |
| Schleedoorn 2016 [ | EndoKey Group (international) | Endometriosis | Hospital | No funding |
Spertus 2005 [ Spertus 2010 [ | American Heart Association (US) | – | Hospital | Public |
| Sutcliffe 2012 [ | NICE (UK) | – | Primary care | Public |
| Ten Berg 2019 [ | Dutch Childhood Oncology Group | Pediatric febrile neutropenia | Hospital | Public |
| Ueda 2019 [ | Kyoto University, Nara Medical University (Japan) | Low-risk labour care | Hospitals | Public |
| Vasse 2012 [ | International | Psychosocial care in dementia | All | Public |
| Werbrouck 2013 [ | EFFECT project/KCE (BE) | Uterine cancer | Hospital | Private non-profit |
| Wollersheim 2007 [ | IQ healthcare, Radboud UMC (NL) | Oncology, diabetes, antibiotics for pneumonia | – | Not reported |
Methods of guideline-based QI development matched to the steps in the guideline development process
| Item on GIN-McMaster Guideline checklist | Results in methods papers on QI development |
|---|---|
| 1. Organization, Budget, Planning and Training | Funding: 14 of the 30 approaches were publicly funded, 3 were privately funded, 2 were funded both publicly and privately, 1 did not receive funding and for 10 funding was not reported. |
| 2. Priority Setting | See 5. |
| 3. Guideline Group Membership | Criteria for selection of GDG members were reported in 6 articles. Four articles reported selection of a multidisciplinary panel, including methodological competence, experience in quality improvement, policy decision making and knowledge translation. All 6 articles mentioned clinical expertise for the specific health care topic as competence. Criteria for selection of QI development panel members were mentioned in 15 articles. Clinical expertise was a criterion in all 15 articles, methodological experience was reported in 6 of the 15 articles. Patients/lay persons were part of three panels. Six reports did not use a formal panel and in 9 articles the criteria were unclear. |
| 4. Establishing Guideline Group Processes | Group processes were not described in any article. |
| 5. Identifying Target Audience and Topic Selection | Fifteen articles reported criteria for selecting the QI topics and the target audience. The criteria, and phrasing of the criteria, varied from article to article. Criteria for topic selection included relevance for the specific care domain (e.g. primary care), quality of care gap, sound evidence base, feasibility, availability, measurability, reliability, validity, regulatory requirements, unknown quality adherence, expected impact on quality of life, costs, work load, disease severity, potential to reduce health inequities and covering all aspects of the care process. |
| 6. Consumer and Stakeholder Involvement | Patients were included in the QI selection process in 9 of the 30 articles. |
| 7. Conflict of Interest (COI) Considerations | Conflicts of interest considerations for the QI development process were not mentioned in any of the papers. |
| 8. (PICO) Question Generation | See item 5 (QI topic selection). |
| 9. Considering Importance of Outcomes and Interventions, Values, Preferences and Utilities | Seventeen articles reported criteria for QI selection. In 9 of these articles patient outcomes, health gain or importance or clinical effectiveness were part of the criteria. |
| 10. Deciding what Evidence to Include and Searching for Evidence | See item 11. |
| 11. Summarizing Evidence and Considering Additional Information | All articles used evidence of guidelines as starting point for the QI development (this was an inclusion criterion). Thirteen articles report additional sources, e.g. literature searches for existing QI sets or available data. In 7 articles QI development was based on multiple guidelines, and in 9 articles QI were developed based on one guideline. In 1 article this was not specified. |
| 12. Judging Quality, Strength or Certainty of a Body of Evidence | 8 of the 13 articles which report criteria for selecting recommendations as basis for QI development use level of evidence as a criterion; 3 of the 8 approaches use GRADE and suggest that only strong recommendations should be considered for translation into QI. |
| 13. Developing Recommendations and Determining their Strength | See item 12. |
| 14. Wording of Recommendations and of Considerations of Implementation, Feasibility and Equity | Feasibility was mentioned as a criterion for selecting QI (10 articles). Equity was mentioned once, as a criterion for selecting the topic for which the QI were developed. |
| 15. Reporting and Peer Review | Reporting and peer review of QI were not mentioned. |
| 16. Dissemination and Implementation | Implementation: 12 articles report a QI implementation plan as part of their approach, mostly consisting of development of tools and software, and audits. |
| 18. Updating | Updating of QI was not explicitly mentioned in any of the papers. |
Guideline-based QI development reporting standard items and report of these criteria in the method papers
| Reporting standard item | Reported in method papers |
|---|---|
| 1a. Guideline selection: criteria | Selection of guidelines was based on topic and • evidence-based development ( • methodological quality of the guideline ( • use of GRADE ( • structured format ( • no other criterion ( • unclear ( |
| 1b. Guideline selection: appraisal of guidelines | • AGREE ( • criteria not fully specified ( • not reported ( |
| 2. Selection of guideline recommendations | • based on topic ( • impact on patient outcome (n = 4) / burden of illness (n = 1) / clinical utility ( • relevance ( • value for money ( • practice variability ( • scope for improvement ( • priority / feasibility for implementation ( • validity ( • (high) level of evidence (n = 8) / adequate scientific proof ( • direct link to aim of guideline ( • common to more than one guideline ( • unclear ( • no selection ( |
| 3. Selection of performance measures from recommendations | • formal panel method ( • other or informal consensus method ( • not reported (n = 2) • unclear (n = 4) |
| 4. Core attributes of performance measures (criteria for selecting QI) | • relevance (n = 4) • potential for improvement ( • burden of illness ( • cost-effectiveness ( • influenced by service provider (n = 3) • appropriateness ( • evidence base/scientific soundness ( • (strength of) association with patient important outcome ( • feasibility ( • no risk for unintended consequences ( • unambiguous definition ( • data routinely collected ( • measurable ( • applicable ( • reliable ( • precision ( • minimum bias ( • not reported ( • unclear ( |
5. Specification of performance measures Numerator and denominator is specified unambiguously and in detail. | • denominator: population eligible to receive the clinical interventions, numerator: desired intervention and subset of population that should receive it ( • based on algorithm ( • formulation of numerator and denominator in line with formulation of recommendation ( • numerator and denominator including risk adjustment factors ( • clinical researcher drafted an expanded text for each recommendation, using logical operators (e.g. ‘AND’ and ‘OR’) to link descriptive statements to produce numerators and denominators ( • method not specified in detail ( • not reported ( |
| 6. Intended use of performance measure | • quality improvement ( • quality of care delivered ( • monitoring compliance with guideline ( • implementation of care ( • clinical audit ( • pay for performance program ( • not specified ( • unclear ( • not reported ( |
| 7. Practice test of performance measures | • planned ( • retrospective (n = 2) • implicit ( • not reported ( |
| 8. Review and evaluation of performance measure | • plan for evaluation and updating ( • evaluation including criteria for retiring ( • mentioned, but not explained in detail ( • evaluation not reported, often because QI were developed but not yet implemented ( |
| 9a. Composition of the panel | • monodisciplinary ( • multidisciplinary ( • panel composition not reported ( |
| 9b. Composition of the panel: patient involvement | • yes ( • no ( • depends on guideline ( • not reported ( |
amultiple criteria per methodological framework